Roux-en-Y gastric bypass (RYGB) is considered as the revisional procedure of choice. However, revisional bariatric Selleckchem SN-38 surgery is associated with relatively higher rates of complications. The aim

of the current study is to analyse our single-centre experience with patients requiring revisional RYGB following primary VBG.

Retrospective review of the prospectively collected database identified 153 patients who underwent RYGB as a revisional procedure after VBG from Feb 2004-Feb 2011. Early and late complications, weight data and resolution of symptoms related to gastric outlet obstruction were analysed.

One hundred twenty-three females and 30 males underwent revisional RYGB post VBG. Mean age was 44.4 (15-74) years with a mean pre-operative body mass index (BMI) of 34.2 (23.5-65.5) kg/m(2). Mean hospital stay was 4.3 days. Early complication rate was 3.9 % with a 30-day re-operation rate of 1.3 %. Mortality and leak rate were zero. After a mean follow-up of 48 months, the mean BMI decreased significantly to

28.8 kg/m(2) and a complete resolution of the obstructive symptoms was achieved in nearly all patients. Late complications developed in 11 (7.7 %) of the patients of which seven (4.9 %) required surgery.

Revisional RYGB following VBG is technically challenging but safe Elafibranor cost with low rates of morbidity and mortality, comparable to primary RYGB. It produces a significant reduction in body weight and in symptoms selleck kinase inhibitor resolution. We recommend RYGB as the procedure of choice

in patients requiring revisional surgery following VBG.”
“Background: Hypercholesterolemia is a strong risk factor for myocardial infarction (MI). There is scarce information regarding lipoprotein levels among patients with MI in Latin America as well as about the association of very early statin therapy during the course of acute MI.

Hypothesis: Very early statin prescription might be associated with a reduction on in-hospital mortality in MI patients with nearly normal lipid levels.

Methods: Prospective registry database analysis of MI patients admitted between 2001 and 2007 at a single university hospital from which demographics, treatments, clinical variables, and mortality were assessed. Patients naive to statin therapy were divided in 2 groups, according to whether they received (group A) or did not receive (group B) statins during the first 24 hours after admission.

Results: In the 1465 patients analyzed, mean plasma levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol (HDL-C) were 197, 117, and 44 mg/dL, respectively, and 41.8% had HDL-C <= 40 mg/dL. Among statin naive patients (n=1272), 67% were classified in group A and 33% in group B. Overall in-hospital mortality was 4.1%: 1.8% in group A and 8.5% in group B.